Cancer Drug Prices Increased $8,500 Per Year Since 1995 January 23, 2015Vol.41 No.03By Matthew Bin Han Ong
CMS Opens Door to Coverage of Comprehensive Genomic Sequencing January 23, 2015Vol.41 No.03By Paul Goldberg
Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up January 02, 2015Vol.37 No.12
TCCL Archive Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study January 02, 2015Vol.37 No.12
Drugs & Targets FDA Grants Approvals to Lynparza, Blincyto, Xgeva, Gardasil 9 and Cyramza January 02, 2015Vol.37 No.12
